PARP1 and lymphoma: For instance, in the chicken lymphoma DT40 cell line, talazoparib was found to be 100‐fold more potent in PARP‐1 ‘trapping’ than rucaparib and olaparib [25], because rucaparib and olaparib were not effective ‘trappers’.